import type { BlogArticle } from '../blog-types';

export const article: BlogArticle = {
  slug: 'peptide-research-reproductive-fertility-kisspeptin-bpc157-gonadal-axis',
  title: 'Peptide Research for Reproductive and Fertility Biology: Kisspeptin, BPC-157, and Gonadal Axis Study Design',
  description:
    'A comprehensive researcher\'s guide to reproductive biology peptide research: kisspeptin HPG axis protocols, BPC-157 in reproductive tissue models, oxytocin in parturition and social bonding, hormone endpoint design, and study considerations for fertility researchers.',
  category: 'Research Fundamentals',
  readMinutes: 11,
  publishedAt: '2026-05-31',
  ogImage: '/og/products/bpc-157.png',
  body: [
    {
      type: 'paragraph',
      text: 'Reproductive biology represents one of the most complex and hormonally integrated fields in biomedical research. Peptides play central roles across the HPG axis — from hypothalamic kisspeptin pulse generation through pituitary LH/FSH secretion to gonadal steroidogenesis, gametogenesis, and tissue remodeling. BPC-157, oxytocin, PT-141, and kisspeptin each engage distinct but complementary pathways relevant to fertility, reproductive tissue health, and neuroendocrine regulation of reproduction.',
    },
    {
      type: 'heading',
      text: 'Kisspeptin and the HPG Axis: Core Reproductive Biology',
    },
    {
      type: 'paragraph',
      text: 'Kisspeptin (KISS1 gene products; KP-54, KP-14, KP-13, KP-10 C-terminal amide variants) acts as the master regulator of the HPG axis via GPR54 (KISS1R) Gq/PLC-β/IP3-DAG signaling. The two hypothalamic kisspeptin neuron populations — arcuate nucleus (ARC) and anteroventral periventricular nucleus (AVPV) — serve distinct functions.',
    },
    {
      type: 'paragraph',
      text: 'ARC kisspeptin neurons co-express neurokinin B (NKB) and dynorphin (KNDy neurons) and generate the ultradian GnRH/LH pulse generator via autocrine NKB→NK3R excitation and dynorphin→κ-opioid receptor inhibition. They also mediate gonadal sex steroid negative feedback: estradiol (E2) and testosterone (T) suppress ARC KISS1 mRNA expression via ERα and AR, respectively.',
    },
    {
      type: 'paragraph',
      text: 'AVPV kisspeptin neurons are E2-sensitive via positive feedback — the only hypothalamic population showing increased firing with rising E2, driving the preovulatory LH surge. This E2-positive feedback is female-specific in most rodent species, requiring estrous cycle synchronization protocols in female study designs.',
    },
    {
      type: 'heading',
      text: 'Kisspeptin Research Protocols: KP-10 vs KP-54',
    },
    {
      type: 'paragraph',
      text: 'Kisspeptin-10 (KP-10) and kisspeptin-54 (KP-54) differ primarily in pharmacokinetics rather than intrinsic GPR54 potency (both ~1–5 nM Ki). KP-10 has a plasma half-life of 4–9 minutes (neprilysin-dominated clearance), making it ideal for IV bolus acute LH pulse studies. A single IV bolus of 1–10 nmol/kg produces a clean, rapid LH pulse in rodents (Dhillo 2005 JCEM: 3× LH elevation, peak at ~15 min, resolved by 60 min).',
    },
    {
      type: 'paragraph',
      text: 'KP-54, with its 27–30 minute plasma half-life, is appropriate for sustained GPR54 stimulation studies (chronic SC dosing, proestrus LH surge induction). However, continuous IV infusion of KP-54 at high doses causes receptor desensitization — paradoxical suppression of LH secretion via GPR54 downregulation. For SC chronic protocols, use 100–500 nmol/kg/day (osmotic minipump for constant delivery) with pre-defined endpoint windows to avoid desensitization confounds.',
    },
    {
      type: 'table',
      headers: ['Parameter', 'KP-10', 'KP-54'],
      rows: [
        ['Sequence length', '10 aa', '54 aa'],
        ['Plasma half-life', '4–9 min', '27–30 min'],
        ['GPR54 intrinsic potency (Ki)', '~1–5 nM', '~1–5 nM'],
        ['Preferred route', 'IV bolus', 'SC chronic or IV infusion (low dose)'],
        ['Acute LH pulse study', '✓ Ideal', 'Suboptimal (slower Tmax)'],
        ['Proestrus surge induction', 'Not recommended', '✓ 150–250 nmol/kg SC at ZT15–16'],
        ['Chronic pulsatile protocol', 'SC clearance too fast', '✓ 200–300 nmol/kg/day osmotic pump'],
        ['Desensitization risk', 'Low (rapid clearance)', 'High at continuous >1 nmol/kg/h IV'],
        ['Rodent IV dose (acute)', '1–10 nmol/kg', '0.3–3.0 nmol/kg/h infusion'],
        ['Required control', 'P-234 GPR54 antagonist', 'P-234 GPR54 antagonist + desensitization arm'],
      ],
    },
    {
      type: 'heading',
      text: 'BPC-157 in Reproductive Tissue Research',
    },
    {
      type: 'paragraph',
      text: 'BPC-157 (Body Protection Compound-157) shows cytoprotective and angiogenic effects in multiple reproductive tissue models, driven by its eNOS/NO, VEGFR2/VEGF, and FAK/paxillin signaling axes. In ovarian tissue, BPC-157 reduces ischemia-reperfusion injury in torsion/detorsion models — NO/eNOS-mediated vessel preservation reduces follicular apoptosis (Bcl-2/Bax ratio improvement, TUNEL endpoint). Published rodent data (Sikiric group, 10 µg/kg IP daily × 7d) show BPC-157 preserves antral follicle counts and reduces cortical fibrosis after 2-hour ischemic intervals.',
    },
    {
      type: 'paragraph',
      text: 'In testicular torsion models (180° for 1–4 hours, standard scrotal approach), BPC-157 at 10 µg/kg IP preserves seminiferous tubule architecture (Johnsen score improvement vs vehicle), reduces Leydig cell apoptosis, and maintains intratesticular testosterone (measured by radioimmunoassay from interstitial fluid). L-NAME (10 mg/kg IP) partially abrogates these effects, confirming eNOS/NO involvement. VEGFR2 inhibitor SU5416 (5 mg/kg IV) provides additional pathway dissection.',
    },
    {
      type: 'paragraph',
      text: 'In endometriosis surgical models (endometrial fragment transfer to peritoneum), BPC-157 at 10 µg/kg IP BID reduces lesion volume and vascularization (CD31 vessel density) by ~40–50% vs vehicle at day 28, consistent with its role as an angiogenesis normalizer (not merely pro-angiogenic — it appears to direct physiological angiogenesis while suppressing pathological neovascularization in established models).',
    },
    {
      type: 'heading',
      text: 'Oxytocin in Parturition and Bonding Research',
    },
    {
      type: 'paragraph',
      text: 'Oxytocin (OT), produced in paraventricular nucleus (PVN) and supraoptic nucleus (SON) magnocellular neurons, regulates uterine contractility via myometrial OTR Gq/PKC/Ca²⁺ signaling and social bonding via CNS OTR in limbic/PFC circuits. Its dual role — peripheral endocrine (parturition, lactation) and central neuropeptide (social behavior, stress axis) — makes intranasal vs IP vs IV route selection critical.',
    },
    {
      type: 'paragraph',
      text: 'For parturition/uterine contractility research: IV or IP delivery in late-gestation rodents (E18–E19 in mice, E20–E21 in rats) activates myometrial OTR. Published doses: 0.1–1 IU/kg IV (human clinical equivalent), or 1–3 mg/kg IP for pharmacological stimulation. Uterine contractility endpoints include isometric tension recording from isolated uterine strips, in vivo tocometry (strain gauge telemetry), and delivery timing (onset, interval, total duration).',
    },
    {
      type: 'paragraph',
      text: 'For CNS/behavioral reproductive endpoints (partner preference, maternal behavior, social recognition): intranasal delivery is required. Peripheral OT at physiological doses does not cross the BBB. Mouse protocol: 5 µL/nostril bilateral at 0.4–1.0 mg/mL in isotonic saline pH 4.5–5.5 (no BAC water — benzyl alcohol disrupts olfactory epithelia), using a gel-loading pipette tip at a 45° head-tilt angle. Begin behavioral testing 15–30 minutes post-administration.',
    },
    {
      type: 'heading',
      text: 'PT-141 (Bremelanotide) in Reproductive Arousal Research',
    },
    {
      type: 'paragraph',
      text: 'PT-141 (cyclic α-MSH analog, MC1R/MC3R/MC4R agonist) activates reproductive arousal circuits via CNS MC4R in PVN/mPOA oxytocinergic neurons — a mechanism entirely distinct from peripheral PDE5 inhibitors. In female rodents, SC PT-141 at 80–160 µg/kg increases proceptive behaviors (lordosis/solicitation frequency) and partner approach latency reduction. MC4R-selective antagonist HS014 (2 mg/kg IP) dissects MC4R-mediated arousal from MC1R-mediated pigmentation and MC3R-mediated metabolic effects.',
    },
    {
      type: 'paragraph',
      text: 'Critical study design consideration: PT-141 causes nausea/conditioned taste aversion at >160 µg/kg via MC3R at area postrema. Pica scoring (kaolin consumption as rodent surrogate for nausea) should accompany all arousal behavioral paradigms to distinguish true pro-sexual effects from behavioral suppression due to malaise. Co-administration of NK1R antagonist maropitant can reduce nausea without blocking MC4R reproductive circuits (confirming on-target arousal vs off-target emesis).',
    },
    {
      type: 'heading',
      text: 'Hormone Endpoint Design: LH, FSH, Testosterone, Estradiol, and Progesterone',
    },
    {
      type: 'paragraph',
      text: 'Hormone endpoints in reproductive research require careful standardization of sampling time, estrous cycle phase, and collection method. For male rodents: collect trunk blood at ZT2–4 (early light phase, testosterone trough provides low CV baseline), or ZT12–14 (activity-phase peak) depending on whether nadir or peak is the relevant endpoint. Isoflurane anesthesia before decapitation significantly suppresses testosterone (20–40%) — maintain consistent short anesthesia-to-collection windows (<60 seconds).',
    },
    {
      type: 'table',
      headers: ['Hormone', 'Preferred Sample', 'Timing', 'Validated Kit', 'Key Notes'],
      rows: [
        ['LH (rodent)', 'Serum (no EDTA)', 'Serial q6min tail-nick protocol', 'Crystal Chem #80552', 'Acid-ethanol extraction not needed for LH; batch same plate'],
        ['FSH', 'Serum', 'ZT2–4 single-point', 'Crystal Chem #80556', 'FSH less pulsatile than LH; single timepoint adequate'],
        ['Testosterone', 'Serum', 'ZT2–4 (nadir) or ZT12–14 (peak)', 'Crystal Chem #80508', 'EDTA plasma causes false elevation; serum only'],
        ['Estradiol (E2)', 'Serum, proestrus morning', 'ZT0–2 for preovulatory surge', 'Crystal Chem #80270', 'Highest sensitivity required; low baseline in males'],
        ['Progesterone', 'Serum, diestrus 2 / metestrus', 'ZT6–10', 'Crystal Chem #80671', 'Luteal-phase peak; varies with CL number'],
        ['Kisspeptin', 'Plasma (EDTA+aprotinin)', 'ZT0–4', 'Phoenix Pharmaceuticals #RK-048-32', 'Low pg/mL range; immediate freezing critical'],
        ['GnRH', 'Hypophyseal portal blood', 'Requires pituitary portal cannulation', 'R&D ELISA', 'Peripheral plasma GnRH unmeasurable (very low concentration)'],
        ['Inhibin B', 'Serum', 'ZT2–4', 'Ansh Labs A-31 (rat)', 'Sertoli/granulosa cell marker; FSH suppressor'],
      ],
    },
    {
      type: 'heading',
      text: 'Estrous Cycle Standardization Protocol',
    },
    {
      type: 'paragraph',
      text: 'Female rodent reproductive research requires estrous cycle staging for all endpoints. Vaginal cytology (saline lavage + wet-mount microscopy): proestrus = large rounded nucleated epithelial cells + some leukocytes; estrus = cornified anucleated cells predominate; metestrus = mixed cornified + leukocytes; diestrus = predominantly leukocytes + small epithelial cells. Cycle 4–5 days in rats, 4–5 days in mice (shorter, less predictable). Record cycle phase for every animal at every endpoint collection.',
    },
    {
      type: 'paragraph',
      text: 'For hormonal synchronization: OVX (ovariectomy) + exogenous steroid replacement eliminates cycle variability. E2 replacement: silastic capsule (4 mm length, 0.05 mg/mL E2 in sesame oil) produces stable serum E2 ~20–40 pg/mL. OVX + E2 replacement is the gold standard for studying kisspeptin GPR54 signaling independent of endogenous cycle variation. OVX alone dramatically upregulates OTR expression (E2-dependent OTR promoter) — a confound for oxytocin behavioral studies that requires OVX + E2 replacement normalization.',
    },
    {
      type: 'heading',
      text: 'Reproductive Model Selection Guide',
    },
    {
      type: 'table',
      headers: ['Model', 'Species', 'Target', 'Key Compounds', 'Endpoint Window', 'Notes'],
      rows: [
        ['Testicular torsion/detorsion', 'Rat (preferred)', 'Leydig + Sertoli cell protection', 'BPC-157 10 µg/kg IP', '7–14 days post-detorsion', 'Standardize torsion angle (180°) and ischemia duration (1–4h)'],
        ['Ovarian I/R (torsion)', 'Mouse/Rat', 'Follicle preservation, angiogenesis', 'BPC-157 10 µg/kg IP', '7–14 days', 'Count antral follicles; TUNEL; CD31 vessel density'],
        ['Endometriosis (surgical)', 'Rat', 'Lesion angiogenesis, fibrosis', 'BPC-157 10 µg/kg IP BID', '28 days', 'Standardize fragment size; blinded lesion volume scoring'],
        ['Proestrus LH surge', 'Female rat', 'Kisspeptin/GnRH axis', 'KP-54 150–250 nmol/kg SC', 'ZT15–17 (surge window)', 'Serial q10min LH sampling via tail-nick'],
        ['Hypogonadotropic hypogonadism (GnRH-KO)', 'GPR54-KO or Kiss1-KO mouse', 'Kisspeptin mechanism', 'KP-10 1–10 nmol/kg IV', 'Acute 60-min post-injection', 'GPR54-null confirms on-target; Jackson Lab stock #017495'],
        ['Uterine contractility', 'Late-gestation rat (E20–21)', 'Parturition, OT signaling', 'Oxytocin 1 IU/kg IV or 1–3 mg/kg IP', 'Acute 30-min recording', 'Isometric tension or in vivo tocometry'],
        ['Partner preference (vole model)', 'Prairie vole (Microtus ochrogaster)', 'OTR-mediated pair bonding', 'Oxytocin IN 5 µL/nostril', '24h partner preference test', 'Monogamous model; meadow vole (M. pennsylvanicus) as OTR-low control'],
        ['Female proceptive behavior', 'Ovariectomized rat + E2/P', 'MC4R arousal pathway', 'PT-141 80–160 µg/kg SC', '30–90 min post-injection', 'Pica scoring mandatory; HS014 MC4R antagonist control'],
      ],
    },
    {
      type: 'heading',
      text: 'GLP-1 Agonists and Reproductive Function',
    },
    {
      type: 'paragraph',
      text: 'GLP-1 receptor expression in reproductive tissues has attracted growing research interest. GLP-1R is expressed in Sertoli cells and Leydig cells (testis), ovarian granulosa cells, and endometrium. In vitro data show semaglutide and liraglutide increase cAMP/PKA in granulosa cell cultures at 10–100 nM, modulating IGF-1 receptor sensitization and steroidogenesis (estradiol production). However, caution is warranted: GLP-1 agonist-induced weight loss can improve reproductive outcomes in DIO/insulin-resistant models via restored kisspeptin pulsatility — confounding direct GLP-1R vs indirect metabolic mechanism dissection.',
    },
    {
      type: 'paragraph',
      text: 'For GLP-1 reproductive studies, pair-fed controls are mandatory. The dramatic weight reduction from semaglutide (0.1–0.3 mg/kg SC 1×/week in DIO C57BL/6J) independently restores kisspeptin ARC expression (leptin-permissive AMPK signaling in ARC kisspeptin neurons), LH pulse frequency, and testosterone in obese male rodents. Ex-9-39 (100 nmol/kg IP, GLP-1R antagonist) administered alongside semaglutide allows metabolic weight-loss vs direct GLP-1R reproductive signaling to be dissected.',
    },
    {
      type: 'heading',
      text: 'Preclinical Dosing Reference: Reproductive Research',
    },
    {
      type: 'table',
      headers: ['Compound', 'Dose', 'Route', 'Frequency', 'Species', 'Reproductive Application', 'Key Reference'],
      rows: [
        ['KP-10', '1–10 nmol/kg', 'IV bolus', 'Single acute', 'Rat/Mouse', 'Acute LH pulse, GPR54 agonism', 'Dhillo 2005 JCEM'],
        ['KP-54', '150–250 nmol/kg', 'SC', 'Single (proestrus surge)', 'Rat', 'LH surge induction at ZT15–16', 'Dhillo 2007'],
        ['KP-54 (chronic)', '200–500 nmol/kg/day', 'Osmotic minipump SC', 'Continuous', 'Rat', 'Pulsatile vs continuous dissection', 'Abbara 2017 NEJM (human)'],
        ['BPC-157', '10 µg/kg', 'IP', 'Daily', 'Rat/Mouse', 'Testicular torsion, ovarian I/R, endometriosis', 'Sikiric group'],
        ['Oxytocin (peripheral)', '1 IU/kg', 'IV', 'Single acute', 'Rat (E20–21)', 'Parturition/uterine contractility', 'Standard uterine pharmacology'],
        ['Oxytocin (CNS/IN)', '0.4–1.0 mg/mL, 5 µL/nostril', 'IN', 'Acute, 15–30 min pre-test', 'Mouse', 'Social behavior, maternal behavior', 'Neumann 2013 review'],
        ['PT-141', '80–160 µg/kg', 'SC', 'Single acute', 'Rat/Mouse', 'Female proceptive behavior, MC4R arousal', 'Kingsberg 2019 RECONNECT'],
        ['Semaglutide', '0.1–0.3 mg/kg', 'SC', '1×/week', 'DIO C57BL/6J', 'Metabolic rescue of HPG function (pair-fed controls required)', 'STEP 1; DIO models'],
      ],
    },
    {
      type: 'heading',
      text: 'Reconstitution and Storage for Reproductive Research',
    },
    {
      type: 'table',
      headers: ['Compound', 'Solvent', 'Stock Concentration', 'Storage Lyophilized', 'Storage Reconstituted', 'Special Notes'],
      rows: [
        ['KP-10', 'Isotonic saline (pH 4.5–5.5)', '0.1–1.0 mg/mL', '-20°C', '4°C, use within 4 hours', 'KP-10 is unstable in neutral PBS; low pH slows NEP degradation at injection site'],
        ['KP-54', 'Isotonic saline pH 5.0', '0.5–2.0 mg/mL', '-20°C', '4°C, 14 days', 'No BAC water; slight opacity normal at high concentration'],
        ['BPC-157', 'BAC water (0.9% BZA) or sterile saline', '500 µg/mL – 1 mg/mL', '-20°C', '4°C, 21 days (BAC water)', 'For mucosal/oral studies use sterile saline (BAC water alters epithelial barrier)'],
        ['Oxytocin (IN)', 'Isotonic saline pH 4.5–5.5 (NO BAC water)', '0.4–1.0 mg/mL', '-20°C', '4°C, 7 days', 'BAC water is retinotoxic and disrupts olfactory neuroepithelium — use only pH-buffered saline for IN delivery'],
        ['Oxytocin (IV/IP)', 'Sterile isotonic saline', '0.1–0.5 mg/mL', '-20°C', '4°C, 7 days', 'Prepare fresh for parturition/uterine studies; avoid excessive freeze-thaw of reconstituted solution'],
        ['PT-141', 'BAC water (0.9% BZA)', '1–2 mg/mL', '-20°C', '4°C, 21 days', 'Amber vials; light-sensitive aromatic residues; swirl gently'],
        ['Semaglutide', 'BAC water (0.9% BZA)', '5 mg/mL stock', '-20°C', '4°C, 28 days', 'Low-bind tubes for dilutions <0.1 mg/mL; no PP vials (adsorption)'],
      ],
    },
    {
      type: 'heading',
      text: '6 Research Design Considerations',
    },
    {
      type: 'list',
      items: [
        'Estrous cycle staging is non-negotiable for all female rodent reproductive studies — uncontrolled cycle phase introduces 3–4× variation in LH, E2, OTR density, and behavioral endpoints. Either stage all animals and randomize by cycle phase, or use OVX + steroid replacement for controlled hormonal background.',
        'Pair-fed controls for GLP-1 agonist reproductive studies: caloric restriction alone restores kisspeptin expression and HPG function in obese rodents. Pair-fed controls matched to the GLP-1-treated group\'s caloric intake allow metabolic vs direct GLP-1R reproductive effects to be dissected.',
        'Housing testosterone confound: group-housed males show 20–40% lower testosterone than individually housed males due to social hierarchy suppression. Standardize housing to single or group, document cage position, and randomize housing groups across treatment conditions.',
        'Serial LH pulse capture (q6-min sampling × 6 hours via jugular cannula or tail-nick) is required for kisspeptin pulse frequency studies — single timepoint LH is nearly meaningless given its pulsatile nature (coefficient of variation >100% at a single timepoint).',
        'Pica scoring (kaolin consumption per 24 hours) is mandatory for PT-141 behavioral studies at doses ≥100 µg/kg. Conditioned taste aversion from nausea will suppress all behavior, mimicking pro-sexual effects in controls. Maropitant NK1R antagonist dissects nausea from MC4R reproductive effects.',
        'Gonadotropin-releasing hormone (GnRH) positive control (5–50 ng/kg IV) validates LH responsiveness of the pituitary in kisspeptin studies. If GnRH triggers LH release but KP-10 does not, the blockade is at the kisspeptin receptor level — confirming compound specificity for GPR54 over pituitary competence.',
      ],
    },
    {
      type: 'callout',
      text: 'For LH pulse studies, the 6-minute serial tail-nick sampling protocol (Piet 2015 JNeurosci) requires extensive habituation — 5+ days of daily 3-minute handling before sampling day. Non-habituated rodents show corticosterone elevations that suppress LH for 30–60 minutes, completely masking the endpoint.',
    },
    {
      type: 'heading',
      text: 'Endpoint Selection Table: Reproductive Biology',
    },
    {
      type: 'table',
      headers: ['Endpoint', 'Method', 'Application', 'Timing', 'Key Compounds'],
      rows: [
        ['LH pulse frequency/amplitude', 'Serial q6min serum RIA (Crystal Chem #80552)', 'GnRH pulse generator activity', '6h telemetry window ZT2–8', 'Kisspeptin, BPC-157 (indirect)'],
        ['Intratesticular testosterone', 'Interstitial fluid RIA after tissue press', 'Leydig cell steroidogenesis', 'ZT2–4 (peak) or ZT12–14', 'BPC-157, semaglutide, kisspeptin'],
        ['Antral follicle count', 'H&E serial sections, 100 µm intervals', 'Ovarian reserve', 'Day 7–14 post-ischemia or protocol end', 'BPC-157, GHK-Cu (emerging)'],
        ['Johnsen score (testis)', 'H&E seminiferous tubule histology 1–10 scale', 'Spermatogenesis integrity', 'Day 7–28 post-torsion', 'BPC-157'],
        ['Endometriosis lesion volume', 'Caliper × π/6 formula', 'Lesion angiogenesis/fibrosis', 'Day 28 post-surgery', 'BPC-157'],
        ['Lordosis quotient (LQ)', 'Lordosis counts / mount counts × 100', 'Female proceptive behavior', '30–90 min post-injection', 'PT-141, oxytocin (IN)'],
        ['Partner preference index (PPI)', 'Time with partner vs stranger / total social time', 'Pair bonding', '24h two-chamber test', 'Oxytocin (IN)'],
        ['Pica score', 'Kaolin pellet consumption (g/24h)', 'Nausea control for PT-141', '24h post-injection', 'PT-141 (mandatory control)'],
        ['GPR54 IHC (ARC/AVPV)', 'kisspeptin/NKB/GPR54 antibodies', 'KNDy neuron counting, activation state', 'End of study', 'Kisspeptin (mechanism)'],
        ['E2-dependent OTR density (uterus)', 'Radioligand binding or OTR IHC', 'Oxytocin sensitivity', 'Proestrus or 24h post-E2 priming', 'Oxytocin'],
        ['Sperm parameters', 'CASA motility analysis + morphology', 'Spermatogenesis output', 'Cauda epididymis at endpoint', 'BPC-157 (torsion protection)'],
        ['CD31 vessel density (ovary/endometrium)', 'IHC + ImageJ vessel counting', 'Angiogenesis endpoint', 'Day 7–28', 'BPC-157, GHK-Cu'],
      ],
    },
    {
      type: 'heading',
      text: 'Related Tools and Resources',
    },
    {
      type: 'paragraph',
      text: 'Reproductive biology studies require careful attention to timing, cycle stage, and hormonal context. The Nexphoria research toolkit offers several resources to support protocol design: the Dosing Frequency Planner for multi-compound injection scheduling, the Half-Life Calculator for washout period determination, the Protocol Template Generator for printable study documents, and the Body-Weight Dose Calculator for allometrically scaled doses. The Peptide Interaction Checker can flag potential receptor overlaps when combining compounds like PT-141 and oxytocin (both engaging PVN oxytocinergic neurons).',
    },
    {
      type: 'disclaimer',
      text: 'All compounds discussed are for research use only (RUO). Not for human consumption, veterinary use, or clinical application. This article is provided for educational purposes to support legitimate scientific research.',
    },
  ],
};
